Vorläufige Sicherheit und antileukämische Aktivität von Sonrotoclax (BGB-11417), einem wirksamen und selektiven BCL2-Inhibitor, bei Patienten mit rezidivierter/refraktärer Akuter Myeloischer Leukämie

Uwe Platzbecker,[1] Pau Montesinos,[2] Paul Cannell,[3] Jake Shortt,[4] Teng Fong Ng,[5] David M. Swoboda,[6] Sophie Leitch,[7] Chun Yew Fong,[8] Andrew H. Wei,[9] Si Cheng,[10] Adam Greenbaum,[11] Yu Liu,[12] Kendra Sweet,[11] Amit Agarwal,[11] Courtney DiNardo[13]

[1]Universitaetsklinikum Leipzig Aör, Leipzig, Germany; [2]Hospital Universitari i Politècnic La Fe, Valencia, Spain; [3]Fiona Stanley Hospital, Murdock, WA, Australia; [4]Monash Health and Monash University, Clayton, VIC, Australia; [5]Gold Coast University Hospital and Griffith University, Queensland, Australia; [6]Tampa General Hospital, Tampa, FL, USA; [7]Te Whatu Ora, Health New Zealand, Waitemata, Auckland, New Zealand; [8]Austin Health, Melbourne, VIC, Australia; [9]Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC, Australia; [10]BeiGene (Shanghai) Co., Ltd., Shanghai, China; [11]BeiGene USA, Inc, San Mateo, CA, USA; [12]BeiGene (Beijing) Co., Ltd., Beijing, China; [13]MD Anderson Cancer Center, Houston, TX, USA

Presented at the Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Medical Oncology 2024; October 11-14, 2024; Basel, Switzerland
Data originally presented at the EHA2024 Hybrid Congress; June 13-16, 2024; Madrid, Spain. Abstract P562

Disclosures for Uwe Platzbecker

- **Honoraria**: Novartis, BMS, Janssen, AbbVie, Curis, Geron, Jazz, Akeso, Gilead, Servier
- **Consulting or advisory role**: AbbVie, BMS, Janssen, Novartis, GSK, Hemavant
- **Speakers bureau**: Novartis, BMS, Janssen, Jazz, Takeda, Sobi, Blueprint, AstraZeneca
- **Travel, accommodations, expenses**: AbbVie, Janssen

Introduction

- AML is the most common acute form of leukemia in adults and has an aggressive disease course[1,2]
- Although treatment with the BCL2 inhibitor venetoclax has improved outcomes in some patients with newly diagnosed AML,[3] venetoclax is not approved in R/R AML[4]
- Sonrotoclax (sonro; BGB-11417), a next-generation BCL2 inhibitor, is more selective and a more pharmacologically potent inhibitor of BCL2 than venetoclax, with a shorter half-life and no accumulation[5]
- Here, we present the preliminary safety and antileukemic activity of sonro + azacitidine (aza) in R/R AML in BGB-11417-103, a phase 1b/2 study

AML, acute myeloid leukemia; BCL2, B-cell lymphoma 2; R/R, relapsed/refractory.

1. Shimony S, et al. *Am J Hematol.* 2023;98(3):502-526; 2. Yi M, et al. *J Hematol Oncol.* 2020;13(1):72; 3. Bazarbachi A. *Bone Marrow Transplant.* 2022;57(2):147-148;
4. Venetoclax. Prescribing information. AbbVie, Inc. 2022; 5. Hu N, et al. AACR 2020. Abstract 3077.

BGB-11417-103 (NCT04771130; EudraCT: 2021-003285-12) Study Design

- BGB-11417-103 is an ongoing, global, multicenter, dose-finding and -expansion study evaluating sonro ± aza in patients with AML, MDS, or MDS/MPN

Eligibility criteria

- AML (non-APL):
  - R/R with no prior BCL2 inhibitor or aza exposure
  - HMA-failure[a] with no prior BCL2 inhibitor exposure
- ECOG PS 0-2
- Not receiving warfarin; moderate or strong CYP3A4 inhibitor or inducer within 5 half-lives

DLT observation window



Sonro (10, 14, 21, or 28 days in 28-day cycle with 4-day ramp-up in cycle 1 starting at 1/8th of the target dose[c])
+
Aza (75 mg/m^2 for 7 days SC or IV)

Part 1 Dose escalation	**Part 2** Safety expansion[d]	**Part 3** Efficacy expansion[d]
3-6 patients	≈10 patients	≈20 patients (R/R AML)

Sonro dose: R/R AML		
40 mg x 10 days 80 mg x 10 days	160 mg x 10 days 160 mg x 28 days	320 mg x 21 days 320 mg x 28 days
Intermediate doses 80 mg x 14 days	160 mg x 14 days 160 mg x 21 days	320 mg x 14 days

[a] HMA failure received ≥1 cycle of HMA and had PD or no PR or better hematologic improvement after 4 cycles of >75% of planned dose. [b] Or cycle 2 initiation. [c] As a precautionary measure for TLS monitoring, patients were hospitalized during the ramp-up period. [d] Safety monitoring committee reviews available data to determine dose escalation in part 1, dose expansion to part 2, and the final RP2D to start part 3.
CYP3A4, cytochrome P450 3A4; HMA, hypomethylating agent; MDS, myelodysplastic syndromes; MPN, myeloproliferative neoplasms; non-APL, nonacute promyelocytic leukemia; TLS, tumor lysis syndrome.

Patient Disposition

- As of March 31, 2024, 51 patients with R/R AML were enrolled and had received sonro + aza treatment
- Four patients (8%) remain on treatment



[a] The efficacy-evaluable population included patients who (1) completed ≥1 treatment cycle (initiated the second cycle) or 42 days, whichever is earlier, or discontinued treatment during the first cycle or (2) had ≥1 response assessment. [b] Defined as evidence for an increase in bone marrow blast percentage and/or increase in absolute blast counts in the blood, both per ELN 2017 response criteria. [c] Hematologic relapse (after CR/CRi) defined as bone marrow blasts ≥5%, reappearance of blasts in the blood, or development of extramedullary disease.
CRi, CR with incomplete hematologic recovery; ELN, European LeukemiaNet.

Baseline Patient Characteristics

	Sonro 40 mg × 10 d (n=7)	Sonro 80 mg × 10 d (n=6)	Sonro 80 mg × 14 d (n=4)	Sonro 160 mg × 10 d (n=8)	Sonro 160 mg × 14 d (n=3)	Sonro 160 mg × 21 d (n=6)	Sonro 160 mg × 28 d (n=9)	Sonro 320 mg × 14 d (n=6)	Sonro 320 mg × 21 d (n=2)	All R/R AML (N=51)
	Aza									
Study follow-up, median (range), months	15.4 (9.2-30.1)	19.9 (1.5-31.7)	0.9 (0.7-2.1)	6.8 (0.2-24.5)	1.7 (1.5-1.7)	5.8 (4.6-7.1)	4.9 (1.2-21.8)	3.8 (1.0-7.6)	7.4 (2.6-12.2)	5.8 (0.2-31.7)
Age, median (range), years	64.0 (36-80)	70.0 (54-78)	57.5 (52-70)	52.5 (36-71)	54.0 (27-67)	53.0 (42-66)	57.0 (29-69)	66.5 (44-74)	70.0 (67-73)	60.0 (27-80)
Male sex, n (%)	3 (43)	3 (50)	2 (50)	5 (63)	2 (67)	4 (67)	6 (67)	3 (50)	1 (50)	29 (57)
AML type, n (%)										
De novo	7 (100)	4 (67)	2 (50)	7 (88)	1 (33)	6 (100)	8 (89)	6 (100)	1 (50)	42 (82)
Secondary	0	2 (33)	2 (50)	1 (13)	2 (67)	0	1 (11)	0	1 (50)	9 (18)
HMA failure, n (%)	0	0	1 (25)	1 (13)	1 (33)	1 (17)	1 (11)	1 (17)	1 (50)	7 (14)
AML risk stratification, n (%)										
Favorable	1 (14)	1 (17)	0	1 (13)	0	0	2 (22)	0	0	5 (10)
Intermediate	3 (43)	1 (17)	2 (50)	4 (50)	0	2 (33)	2 (22)	0	0	14 (27)
Adverse	3 (43)	4 (67)	2 (50)	3 (38)	3 (100)	4 (67)	5 (56)	6 (100)	2 (100)	32 (63)

Baseline Patient Characteristics (cont.)

	Sonro 40 mg × 10 d (n=7)	Sonro 80 mg × 10 d (n=6)	Sonro 80 mg × 14 d (n=4)	Sonro 160 mg × 10 d (n=8)	Sonro 160 mg × 14 d (n=3)	Sonro 160 mg × 21 d (n=6)	Sonro 160 mg × 28 d (n=9)	Sonro 320 mg × 14 d (n=6)	Sonro 320 mg × 21 d (n=2)	All R/R AML (N=51)
	Aza									
Positive genetic abnormality, n (%)	6 (86)	5 (83)	2 (50)	7 (88)	2 (67)	5 (83)	7 (78)	5 (83)	2 (100)	41 (80)
NPM1	2 (29)	1 (17)	0	2 (25)	0	0	3 (33)	1 (17)	0	9 (18)
TP53 aneuploidy	0	0	1 (25)	0	0	1 (17)	0	1 (17)	1 (50)	4 (8)
−17/abn(17p); *TP53* abnormality	1 (14)	1 (17)	0	0	0	0	0	0	0	2 (4)
−7 or del(7q)	1 (14)	0	0	2 (25)	0	1 (17)	2 (22)	0	0	6 (12)
IDH1	0	2 (33)	0	2 (25)	0	0	1 (11)	1 (17)	0	6 (12)
IDH2 R172	1 (14)	1 (17)	0	1 (13)	0	1 (17)	2 (22)	0	0	6 (12)
FLT3-ITD high AR	0	0	0	0	0	0	0	1 (17)	1 (50)	2 (4)
FLT3-ITD low AR	0	1 (17)	0	1 (13)	0	1 (17)	0	0	0	3 (6)
FLT3-TKD	0	0	1 (25)	0	0	0	1 (11)	0	0	2 (4)
−5 or del(5q)	0	1 (17)	0	1 (13)	0	1 (17)	0	0	0	3 (6)
Prior therapy										
Prior aza exposure, n (%)	0	0	1 (25)	0	1 (33)	1 (17)	1 (11)	2 (33)	1 (50)	7 (14)
No. of lines of prior systemic therapy, median (range)	1.0 (1-2)	1.0 (1-2)	1.5 (1-2)	2.0 (1-2)	2.0 (1-2)	2.0 (1-6)	1.0 (1-3)	2.0 (1-3)	1.5 (1-2)	2.0 (1-6)

AR, allelic ratio; ITD, internal tandem duplication; TKD, tyrosine kinase domain.

Overall TEAE Summary

- Six patients had a TEAE leading to death; the 30-day mortality rate was 2%
  - 2 TEAEs related to sonro, aza, and disease: neutropenic sepsis (160 mg x 28 d); pneumonia (320 mg x 14 d)
  - 2 TEAEs leading to death related to PD: pulmonary mucormycosis (160 mg x 14 d); bone marrow failure (160 mg x 28 d)
  - TEAEs leading to death, not related to treatment or disease: aorto-bronchial fistula (160 mg x 28 d); Klebsiella sepsis (160 mg x 10 d)
- 1 DLT (grade 4 thrombocytopenia) occurred in the aza + sonro 320 mg x 14-d cohort
- No laboratory or clinical TLS

Patients, n (%)	All R/R AML (N=51)
Any TEAEs	50 (98)
Grade ≥3	45 (88)
Serious TEAEs	37 (73)
TEAEs leading to death	6 (12)
TEAEs leading to discontinuation	
Aza	7 (14)
Sonro	7 (14)
TEAEs leading to reduction	
Aza	1 (2)
Sonro	7 (14)
TEAEs leading to interruption	
Aza	3 (6)
Sonro	5 (10)

D, day.

TEAEs in ≥20% (All Grades) or ≥10% (Grade ≥3)

- Most common any-grade TEAEs: neutropenia,[a] thrombocytopenia,[b] and nausea
  - Most common grade ≥3 TEAE: neutropenia
  - Grade ≥3 infections and infestations occurred in 24 patients (47%)
- Most common TEAE class leading to treatment discontinuation: infections and infestations (aza, n=4; sonro, n=4)
- Most common TEAEs leading to dose reduction: neutropenia (sonro reduction, n=5); neutrophil count decreased (aza reduction, n=1)



[a] Neutropenia includes the terms *neutropenia* and *neutrophil count decreased*. [b] Thrombocytopenia includes the terms *thrombocytopenia* and *platelet count decreased*. [c] Sepsis is a grouped term excluding fungal sepsis.

In patients with R/R AML, ORR was 54%

- CR/CRh rate: 42%
  Median time to CR/CRh of 1.9 months
- Median duration of CR: 13.1 months
  (median follow-up, 20.8 months)
- Median duration of CR/CRh: 13.1 months
  (median follow-up, 3.5 months)
- Median duration of CR/CRi: 13.1 months
  (median follow-up, 3.5 months)



CR, complete response; CRi, CR with incomplete hematologic recovery; DOR, duration of response; MLFS, morphologic leukemia-free state; ND, not done; NE, not evaluable; ORR, overall response rate; PD, progressive disease; SD, stable disease.

Conclusions

- Sonro + aza combination treatment was generally well tolerated in patients with R/R AML without prior BCL2 inhibitor exposure
  - Across dose cohorts, 1 DLT of grade 4 thrombocytopenia occurred
- Sonro + aza demonstrated antileukemic activity in patients with R/R AML in all dose cohorts
  - The ORR was 54%, of which CR was achieved by 24% and CR/CRh by 42%, and the transplant rate was 20%
- The study stopping criteria has not been met in any of the dose cohorts
- Safety expansion of x 14-day dosing is ongoing in 80 mg, 160 mg, and 320 mg cohorts to determine the recommended phase 2 dose

Acknowledgments

- The authors thank the patients and their families, investigators, co-investigators, and the study teams at each of the participating centers
- This study was supported by BeiGene, Ltd
- Medical writing was provided by Kendall Foote, PhD, of Nucleus Global, an Inizio company, and supported by BeiGene

Corresponding author: Uwe Platzbecker, uwe.platzbecker@medizin.uni-leipzig.de

Backup Slides

Treatment Exposure in R/R AML

- The median number of treatment cycles was 2, with the longest average cycle duration (median, 42.3 days) in the aza + sonro 320 mg x 21 day cohort

	Sonro 40 mg × 10 d (n=7)	Sonro 80 mg × 10 d (n=6)	Sonro 80 mg × 14 d (n=4)	Sonro 160 mg × 10 d (n=8)	Sonro 160 mg × 14 d (n=3)	Sonro 160 mg × 21 d (n=6)	Sonro 160 mg × 28 d (n=9)	Sonro 320 mg × 14 d (n=6)	Sonro 320 mg × 21 d (n=2)	All R/R AML (N=51)
	Aza									
No. of cycles, median (range)	2.0 (2.0-15.0)	10.5 (1.0-28.0)	1.0 (1.0-1.0)	2.5 (1.0-20.0)	1.0 (1.0-2.0)	2.0 (1.0-7.0)	2.0 (1.0-4.0)	2.0 (1.0-5.0)	3.5 (1.0-6.0)	2.0 (1.0-28.0)
Average cycle duration, median (range), days	34.5 (29.5-41.5)	32.7 (21.0-40.9)	26.5 (22.0-44.0)	35.0 (5.0-48.7)	34.0 (23.0-44.0)	36.8 (25.0- 53.0)	35.0 (25.3- 55.0)	40.7 (26.5-46.0)	42.3 (35.7- 49.0)	35.0 (5.0-55.0)
Relative dose intensity (sonro), median (range), %	97.4 (26.0-100)	81.1 (57.0-112.7)	100 (100-100)	100 (33.9-100)	100 (90.9-100)	79.6 (54.9-100)	84.6 (22.0-156.0)	81.1 (47.2-100)	82.1 (64.3-100)	97.4 (22.0-156.0)
Relative dose intensity (aza), median (range), %	100 (52.3-100.3)	87.4 (45.8-101.0)	100.2 (99.8-101.5)	99.8 (73.0-101.1)	100 (85.2-100.0)	99.5 (64.9-103.4)	100 (69.9-100.9)	99.8 (60.5-100.3)	92.7 (84.3-101.1)	99.9 (45.8-103.4)

- The median dose intensity relative to the assigned dose of sonro was >80%, except in the aza + sonro 160 mg x 21 day cohort

Summary of Disease Responses[a]

	Sonro 40 mg × 10 d (n=7)	Sonro 80 mg × 10 d (n=6)	Sonro 80 mg × 14 d (n=3)	Sonro 160 mg × 10 d (n=8)	Sonro 160 mg × 14 d (n=3)	Sonro 160 mg × 21 d (n=6)	Sonro 160 mg × 28 d (n=9)	Sonro 320 mg × 14 d (n=6)	Sonro 320 mg × 21 d (n=2)	All R/R AML (N=50)
					Aza					
CR, n (%)	2 (29)	3 (50)	1 (33)	2 (25)	0	2 (33)	2 (22)	0	0	12 (24)
Time to CR, median (range), months	3.2 (1.5-4.9)	4.1 (3.7-4.6)	0.8 (0.8-0.8)	3.2 (1.9-4.4)	-	1.4 (0.9-1.9)	1.3 (1.1-1.4)	-	-	1.9 (0.8-4.9)
Duration of CR, median (95% CI), months[b]	7.7 (2.3-NE)	18.0 (1.9-NE)	NR (NE-NE)	20.5 (NE-NE)	-	NR (NE-NE)	0.1 (NE-NE)	-	-	13.1 (0.1-20.5)
CR/CRh, n (%)	5 (71)	4 (67)	1 (33)	3 (38)	0	2 (33)	3 (33)	2 (33)	1 (50)	21 (42)
Time to CR/CRh, median (range), months	2.4 (1.2-3.5)	3.9 (1.1-4.6)	0.8 (0.8-0.8)	1.9 (1.0-1.9)	-	1.4 (0.9-1.9)	1.1 (0.8-1.4)	1.9 (1.3-2.4)	7.7 (7.7-7.7)	1.9 (0.8-7.7)
Duration of CR/CRh, median (95% CI), months[b]	8.6 (4.0-NE)	18.0 (1.9-NE)	NR (NE-NE)	20.5 (NE-NE)	-	NR (NE-NE)	NR (0.1-NE)	4.0 (NE-NE)	NR (NE-NE)	13.1 (1.9-20.5)
CR/CRi, n (%)	4 (57)	4 (67)	1 (33)	3 (38)	0	2 (33)	3 (33)	3 (50)	1 (50)	21 (42)
Time to CR/CRi, median (range), months	2.0 (1.2-3.2)	3.0 (1.1-4.1)	0.8 (0.8-0.8)	1.0 (0.8-1.9)	-	1.4 (0.9-1.9)	1.1 (0.8-1.4)	1.2 (0.9-1.3)	7.7 (7.7-7.7)	1.3 (0.8-7.7)
Duration of CR/CRi, median (95% CI), months[b]	8.6 (4.0-NE)	18.0 (1.9-NE)	NR (NE-NE)	20.5 (NE-NE)	-	NR (NE-NE)	NR (0.1-NE)	4.0 (0.1-NE)	NR (NE-NE)	13.1 (1.9-20.5)

[a] Responses were determined using the 2017 European LeukemiaNet criteria and partial hematology recovery criteria for AML. [b] Medians were estimated using the Kaplan-Meier method, with 95% CIs estimated using the Brookmeyer and Crowley method with log-log transformation.
NE, not estimable, NR, not reached.